Inventiva (NASDAQ:IVA) Trading Down 4.4% – Time to Sell?
by Scott Moore · The Cerbat GemInventiva S.A. Sponsored ADR (NASDAQ:IVA – Get Free Report)’s stock price dropped 4.4% on Monday . The company traded as low as $5.04 and last traded at $5.0270. Approximately 313,398 shares were traded during trading, a decline of 30% from the average daily volume of 445,889 shares. The stock had previously closed at $5.26.
Analysts Set New Price Targets
IVA has been the topic of a number of recent analyst reports. Barclays initiated coverage on shares of Inventiva in a research note on Tuesday, January 27th. They set an “overweight” rating and a $18.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research note on Thursday, January 22nd. UBS Group began coverage on shares of Inventiva in a research report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 price objective on the stock. Truist Financial began coverage on shares of Inventiva in a research report on Thursday, March 19th. They issued a “buy” rating and a $13.00 price objective on the stock. Finally, HC Wainwright set a $24.00 price objective on shares of Inventiva and gave the stock a “buy” rating in a research report on Wednesday, January 28th. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $16.56.
Get Our Latest Report on Inventiva
Inventiva Stock Down 4.8%
The stock’s fifty day simple moving average is $6.05 and its 200-day simple moving average is $5.37.
Inventiva (NASDAQ:IVA – Get Free Report) last released its earnings results on Saturday, February 14th. The company reported ($0.16) earnings per share (EPS) for the quarter. The business had revenue of $0.01 million for the quarter. As a group, equities research analysts predict that Inventiva S.A. Sponsored ADR will post -2.08 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Creative Planning purchased a new position in Inventiva in the 2nd quarter valued at about $32,000. Virtu Financial LLC purchased a new position in Inventiva in the 4th quarter valued at about $60,000. XTX Topco Ltd purchased a new position in Inventiva in the 4th quarter valued at about $84,000. Cerity Partners LLC purchased a new position in Inventiva in the 4th quarter valued at about $93,000. Finally, NewEdge Advisors LLC purchased a new position in Inventiva in the 3rd quarter valued at about $116,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.
Inventiva Company Profile
Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.
The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.